Hemodynamics, fluids & transfusion

DiCARTTM device to measure capillary refill time: a validation study in patients with acute circulatory failure

J Clin Monit ComputPublished Validation study

Authors' conclusion

The DiCART™ device showed poor agreement with clinical CRT in patients with acute circulatory failure

Study context

Population
Patients with acute circulatory failure; Capillary Refill Time (CRT) measured on fingertip, chest and knee
Participants
25 patients
Comparison
Automated DiCART™ CRT vs clinically measured CRT
Outcome
Agreement between CRTDiCART and CRTCLIN (ICC and Bland and Altman analysis)
Methodological detailscomparative interventional study, single-centre, blinded operators, Three measurements per site averaged; clinical and DiCART™ measurements by two different operators, each blinded to the results
  • Comparative interventional study
  • Single-centre
  • Blinded operators
  • Three measurements per site averaged; clinical and DiCART™ measurements by two different operators, each blinded to the results

Performance

As reported in the abstract

Agreement CRTCLIN vs CRTDiCART, all measurement sites

Intraclass correlation coefficient (ICC)

0.46

95% CI 0.32–0.59

Agreement CRTCLIN vs CRTDiCART, all measurement sites

Mean bias

0.23 s

95% CI −0.17 to 0.64

upper Limit of Agreement (LoA) 2.77s (95% CI 2.44, 3.20); lower LoA - 2.30s (−2.73, −1.97)

Further findings

ICC

OutcomeCRTDiCARTCRTCLIN
Intra-observer agreement (ICC)0.43 (95% CI 0.15–0.64)0.85 (95% CI 0.74–0.91)
Inter-observer agreement (ICC)0.410.86 (95% CI 0.76–0.92)
  • Inter-observer agreement (ICC): CRTDiCART 95% CI lower bound 0.14; upper bound misprinted in abstract

Original publication

DiCARTTM device to measure capillary refill time: a validation study in patients with acute circulatory failure. J Clin Monit Comput. Published 26 February 2025. doi:10.1007/s10877-025-01271-5

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.